Xeomin Approved For Expanded Indication in Pediatric Upper Limb Spasticity Patients with Cerebral Palsy Following FDA Label Update

Дата публикации: 26-06-2026 04:06:18

RALEIGH, N.C. – June 26, 2026 – Merz Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. Prescribing Information for Xeomin® (incobotulinumtoxinA), expanding the pediatric...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	FDA updates Xeomin label for spasticity-associated cerebral palsy	0	5	26-06-2026
2	FDA Approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer	0	11.85	10-07-2026
3	Skyrizi (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease	0	13.95	26-06-2026
4	FDA Approves Sarclisa Escena (isatuximab-irfc) Subcutaneous Injection for the Treatment of Multiple Myeloma	0	12.93	10-07-2026
5	FDA Approves Leqembi Iqlik (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease	0	13.38	13-07-2026
6	Glenmark Receives U.S. FDA Approval to Expand the Use of Ryaltris Nasal Spray for Children Aged 6 to Less Than 12 Years	0	13.57	21-07-2026
7	FDA Approves Lipfendra (enlicitide) Oral PCSK9 Inhibitor to Reduce LDL-C in Adults with Hypercholesterolemia	0	15.63	16-07-2026
8	FDA Approves Orzeyful (oveporexton) to Treat the Underlying Cause of Narcolepsy Type 1	0	19.75	05-08-2026
9	FDA Grants Accelerated Approval to Zenbexus (iberdomide) in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone for the Treatment of Multiple Myeloma	0	11.39	13-08-2026
10	FDA Approves Arcutis’ Zoryve (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2	0	19.68	29-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 10.02. Источник: www.drugs.com.